Prestige Consumer Healthcare (NYSE:PBH) Reaches New 1-Year Low on Disappointing Earnings

Key Points

• Prestige Consumer Healthcare shares hit a new 52-week low of $64.41 following a disappointing earnings report, with a miss in EPS at $0.95 compared to the expected $1.01.
• The company's revenue for the quarter was reported at $249.53 million, falling short of the $260.71 million consensus estimate and representing a year-over-year decrease of 6.6%.
• Despite the recent challenges, several analysts have maintained a Moderate Buy consensus rating for Prestige, with a target price set at $93.33.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday following a weaker than expected earnings announcement. The company traded as low as $64.41 and last traded at $64.83, with a volume of 82031 shares. The stock had previously closed at $67.61.

The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%. The firm had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. During the same period in the previous year, the company earned $0.90 EPS. Prestige Consumer Healthcare's revenue for the quarter was down 6.6% on a year-over-year basis.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PBH shares. Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Finally, Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $93.33.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in PBH. LPL Financial LLC grew its stake in Prestige Consumer Healthcare by 21.1% during the fourth quarter. LPL Financial LLC now owns 35,198 shares of the company's stock worth $2,749,000 after purchasing an additional 6,123 shares during the period. Franklin Resources Inc. grew its stake in Prestige Consumer Healthcare by 0.7% during the fourth quarter. Franklin Resources Inc. now owns 21,735 shares of the company's stock worth $1,697,000 after purchasing an additional 150 shares during the period. Wells Fargo & Company MN grew its stake in Prestige Consumer Healthcare by 103.0% during the fourth quarter. Wells Fargo & Company MN now owns 199,449 shares of the company's stock worth $15,575,000 after purchasing an additional 101,179 shares during the period. Resona Asset Management Co. Ltd. acquired a new stake in Prestige Consumer Healthcare during the fourth quarter worth approximately $695,000. Finally, Envestnet Asset Management Inc. grew its stake in Prestige Consumer Healthcare by 124.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 169,926 shares of the company's stock worth $13,270,000 after purchasing an additional 94,192 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 3.0%

The firm has a 50 day moving average of $79.26 and a 200 day moving average of $82.06. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of 15.40, a PEG ratio of 1.97 and a beta of 0.43. The company has a quick ratio of 2.82, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.